Logo image of CYTO.CA

CYTOPHAGE TECHNOLOGIES LTD (CYTO.CA) Stock Fundamental Analysis

Canada - TSX Venture Exchange - TSX-V:CYTO - CA2328211081 - Common Stock

0.165 CAD
+0.01 (+3.13%)
Last: 12/24/2025, 7:00:00 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CYTO. CYTO was compared to 0 industry peers in the Unkown industry. CYTO has a bad profitability rating. Also its financial health evaluation is rather negative. CYTO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CYTO had negative earnings in the past year.
CYTO had a negative operating cash flow in the past year.
CYTO.CA Yearly Net Income VS EBIT VS OCF VS FCFCYTO.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

Industry RankSector Rank
ROA -112.63%
ROE -216.73%
ROIC N/A
ROA(3y)-114.73%
ROA(5y)N/A
ROE(3y)-539.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CYTO.CA Yearly ROA, ROE, ROICCYTO.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CYTO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYTO.CA Yearly Profit, Operating, Gross MarginsCYTO.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for CYTO has been increased compared to 1 year ago.
The debt/assets ratio for CYTO has been reduced compared to a year ago.
CYTO.CA Yearly Shares OutstandingCYTO.CA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M 40M 50M
CYTO.CA Yearly Total Debt VS Total AssetsCYTO.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 1M 2M 3M 4M 5M

2.2 Solvency

Based on the Altman-Z score of -8.33, we must say that CYTO is in the distress zone and has some risk of bankruptcy.
A Debt/Equity ratio of 0.56 indicates that CYTO is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF N/A
Altman-Z -8.33
ROIC/WACCN/A
WACCN/A
CYTO.CA Yearly LT Debt VS Equity VS FCFCYTO.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 2M -2M 4M -4M -6M

2.3 Liquidity

A Current Ratio of 1.85 indicates that CYTO should not have too much problems paying its short term obligations.
A Quick Ratio of 1.85 indicates that CYTO should not have too much problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.85
Quick Ratio 1.85
CYTO.CA Yearly Current Assets VS Current LiabilitesCYTO.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 1M 2M 3M 4M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 77.51% over the past year.
EPS 1Y (TTM)77.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CYTO. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYTO.CA Price Earnings VS Forward Price EarningsCYTO.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYTO.CA Per share dataCYTO.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.02 -0.02 -0.04 -0.06

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CYTO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CYTOPHAGE TECHNOLOGIES LTD

TSX-V:CYTO (12/24/2025, 7:00:00 PM)

0.165

+0.01 (+3.13%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners13.05%
Ins Owner ChangeN/A
Market Cap11.05M
Revenue(TTM)N/A
Net Income(TTM)-4.62M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.18
P/tB 5.18
EV/EBITDA N/A
EPS(TTM)-0.08
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0
BVpS0.03
TBVpS0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -112.63%
ROE -216.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-114.73%
ROA(5y)N/A
ROE(3y)-539.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 59.03%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.85
Quick Ratio 1.85
Altman-Z -8.33
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)106.84%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-101.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-66.87%
OCF growth 3YN/A
OCF growth 5YN/A

CYTOPHAGE TECHNOLOGIES LTD / CYTO.CA FAQ

What is the fundamental rating for CYTO stock?

ChartMill assigns a fundamental rating of 1 / 10 to CYTO.CA.


What is the valuation status of CYTOPHAGE TECHNOLOGIES LTD (CYTO.CA) stock?

ChartMill assigns a valuation rating of 0 / 10 to CYTOPHAGE TECHNOLOGIES LTD (CYTO.CA). This can be considered as Overvalued.


How profitable is CYTOPHAGE TECHNOLOGIES LTD (CYTO.CA) stock?

CYTOPHAGE TECHNOLOGIES LTD (CYTO.CA) has a profitability rating of 0 / 10.


How financially healthy is CYTOPHAGE TECHNOLOGIES LTD?

The financial health rating of CYTOPHAGE TECHNOLOGIES LTD (CYTO.CA) is 2 / 10.